Diagnostic utility of p501s (prostein) in comparison to prostate specific antigen (PSA) for the detection of metastatic prostatic adenocarcinoma

Diagnostic Pathology

Volumn 2, Issue 1, 2007, Pages

  Yin, Ming ^a   Dhir, Rajiv ^a   Parwani, Anil V ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 37849012718     PISSN: None     EISSN: 17461596     Source Type: Journal    
DOI: 10.1186/1746-1596-2-41     Document Type: Article

References (24)

1. Acinar adenocarcinoma. FA J.I. Epstein W.C. Allsbrook Jr., S. Bastacky, L. Boccon-Gibod, A.M. De Marzo, L. Egevad, M. Furusato, UM Hamper, WHO Classification of Tumours: Pathology and genetics of tumours of the urinary system and male genital organs Lyon, IARC Press, John N. Eble GSJIEIAS, 2004 162
2. Cancer statistics, 1999. SH Landis T Murray S Bolden PA Wingo, CA Cancer J Clin 1999 49 1 8 31, 1 10200775
3. The course of metastatic disease originating from carcinoma of the prostate. S Plesnicar, Clin Exp Metastasis 1985 3 2 103 110 10.1007/BF01758959 4042459
4. Supraclavicular lymph node: incidence of unsuspected metastatic prostate cancer. K Hematpour CJ Bennett D Rogers CS Head, Eur Arch Otorhinolaryngol 2006 263 9 872 874 10.1007/s00405-006-0066-2 16830117
5. Radical prostatectomy for impalpable prostate cancer: the Johns Hopkins experience with tumors found on transurethral resection (stages T1A and T1B) and on needle biopsy (stage T1C). JI Epstein PC Walsh CB Brendler, J Urol 1994 152 5 Pt 2 1721 1729 7523719
6. Large, organ confined, impalpable transition zone prostate cancer: association with metastatic levels of prostate specific antigen. TA Stamey DD Dietrick MM Issa, J Urol 1993 149 3 510 515 7679754
7. Variation of prostate-specific antigen expression in different tumour growth patterns present in prostatectomy specimens. MP Gallee E Visser-de Jong JA van der Korput TH van der Kwast FJ ten Kate FH Schroeder J Trapman, Urol Res 1990 18 3 181 187 10.1007/BF00295844 1697709
8. Immunohistochemical diagnosis of the metastasizing prostatic carcinoma. J Steffens W Friedmann H Lobeck, Eur Urol 1985 11 2 91 94 2408895
9. Metastatic, sarcomatoid, and PSA- and PAP-negative prostatic carcinoma: diagnosis by fine-needle aspiration. AA Renshaw SR Granter, Diagn Cytopathol 2000 23 3 199 201 10.1002/1097-0339(200009)23:3<199::AID-DC12>3.0.CO;2-4 10945910
10. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. DG Bostwick A Pacelli M Blute P Roche GP Murphy, Cancer 1998 82 11 2256 2261 10.1002/(SICI)1097-0142(19980601)82:11<2256::AID-CNCR22>3.0.CO;2-S 9610707
11. Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. MP Roudier LD True CS Higano H Vesselle W Ellis P Lange RL Vessella, Hum Pathol 2003 34 7 646 653 10.1016/S0046-8177(03)00190-4 12874759
12. Characterization of residual tumor cells following radical radiation therapy for prostatic adenocarcinoma; immunohistochemical expression of prostate-specific antigen, prostatic acid phosphatase, and cytokeratin 8. G Ljung M Norberg L Holmberg C Busch S Nilsson, Prostate 1997 31 2 91 97 10.1002/(SICI)1097-0045(19970501)31:2<91::AID-PROS3>3.0.CO;2-K 9140121
13. Multiple immunoperoxidase markers in benign hyperplasia and adenocarcinoma of the prostate. DW Ellis S Leffers JS Davies AB Ng, Am J Clin Pathol 1984 81 3 279 284 6199966
14. Expression of prostate specific antigen in male breast cancer. PJ Carder V Speirs J Ramsdale MR Lansdown, J Clin Pathol 2005 58 1 69 71 10.1136/jcp.2004.018291 15623486
15. Detection of prostate specific antigen in pancreas and salivary glands: a potential impact on prostate cancer overestimation. AA Elgamal NL Ectors S Sunardhi-Widyaputra HP Van Poppel BJ Van Damme LV Baert, J Urol 1996 156 2 Pt 1 464 468 8683704
16. Immunohistochemical labelling for prostate-specific antigen in breast carcinomas. KA Alanen T Kuopio YU Collan P Kronqvist L Juntti TJ Nevalainen, Breast Cancer Res Treat 1999 56 2 169 176 10.1023/A:1006210627219 10573109
17. PSA immunoreactivity in a parotid oncocytoma: a diagnostic pitfall in discriminating primary parotid neoplasms from metastatic prostate cancer. GF Holmes DW Eisele D Rosenthal WH Westra, Diagn Cytopathol 1998 19 3 221 225 10.1002/(SICI)1097-0339(199809)19:3<221::AID-DC14>3.0.CO;2-G 9741000
18. Identification of naturally processed CD8 T cell epitopes from prostein, a prostate tissue-specific vaccine candidate. RS Friedman AG Spies M Kalos, Eur J Immunol 2004 34 4 1091 1101 10.1002/eji.200324768 15048720
19. Identification and characterization of prostein, a novel prostate-specific protein. J Xu M Kalos JA Stolk EJ Zasloff X Zhang RL Houghton AM Filho M Nolasco R Badaro SG Reed, Cancer Res 2001 61 4 1563 1568 11245466
20. Identification of an HLA-A*0201-restricted T-cell epitope derived from the prostate cancer-associated protein prostein. A Kiessling S Stevanovic S Fussel B Weigle MA Rieger A Temme EP Rieber M Schmitz, Br J Cancer 2004 90 5 1034 1040 10.1038/sj.bjc.6601642 14997204
21. Prostein expression is highly restricted to normal and malignant prostate tissues. M Kalos J Askaa BL Hylander EA Repasky F Cai T Vedvick SG Reed GL Wright Jr. GR Fanger, Prostate 2004 60 3 246 256 10.1002/pros.20043 15176054
22. Practical aspects of planning, building, and interpreting tissue microarrays: the Cooperative Prostate Cancer Tissue Resource experience. A Kajdacsy-Balla JM Geynisman V Macias S Setty NM Nanaji JJ Berman K Dobbin J Melamed X Kong M Bosland J Orenstein J Bayerl MJ Becich R Dhir MW Datta, J Mol Histol 2007 38 2 113 121 10.1007/s10735-006-9054-5 17318343
23. Expressing patterns of p16 and CDK4 correlated to prognosis in colorectal carcinoma. P Zhao YC Hu IC Talbot, World J Gastroenterol 2003 9 10 2202 2206 14562378
24. Distinguishing prostatic from colorectal adenocarcinoma on biopsy samples: the role of morphology and immunohistochemistry. CL Owens JI Epstein GJ Netto, Arch Pathol Lab Med 2007 131 4 599 603 17425391